50
Participants
Start Date
October 20, 2006
Primary Completion Date
August 14, 2009
Study Completion Date
August 14, 2009
Pazopanib
Pazopanib is an oral inhibitor of vascular endothelial growth factor receptor, platelet-derived growth factor receptor, and c-kit kinases
FOLFOX 6
FOLFOX 6 treatment consists of intravenous (IV) oxaliplatin (100 milligram per meter\^2\[mg/m\^2\]), and folinic acid (400 mg/m\^2), IV 5-fluorouracil bolus (400 mg/m\^2) followed by IV 5-fluorouracil (2400 to 3000 mg/m\^2) infusion over 48 hours on Day 1 of every 14-day cycle.
CapeOx
CapeOx treatment consists of IV oxaliplatin (130 mg/m\^2) on Day 1 plus oral capecitabine (1000 mg/m\^2) twice daily on Days 2 through 14 of every 21-day cycle. Reduced CapeOx treatment will be administered according to the same schedule as the CapeOx treatment, but the dose of capecitabine will be reduced to 850 mg/m\^2 twice daily.
GSK Investigational Site, Pārel
GSK Investigational Site, Hyderabad, Andhra Pradesh
GSK Investigational Site, Cambridge
GSK Investigational Site, Oxford
GSK Investigational Site, Sutton
Lead Sponsor
GlaxoSmithKline
INDUSTRY